A2 Milk Investors Did Not Like The Company’s Latest Trading Update!

A2 Milk investors sent shares down over 15% off the back of a negative trading update.

Despite reporting strong underlying demand across its infant milk formula (IMF) portfolio in China, the company disclosed a series of supply chain constraints that will materially affect fourth‑quarter sales, margins, and cash conversion.

The irony is that demand was not an issue, as it has been before. The issue is timing, logistics, and the cumulative effect of multiple operational bottlenecks converging at once. The company now expects lower FY26 IMF sales (particularly China label IMF), additional one‑off supply chain costs, and a delay in cash receipts into FY27. EBITDA margin guidance has been cut from 15.5–16.0% to 14.0–14.5%, and cash conversion expectations have been reduced from 80% to 50%.

The news impacted A2 Milk shares and also led its manufacturing partner Synlait to give an update of its own.

What are the Best ASX Stocks to invest in?

Check our buy/sell tips

Despite Reaction From A2 Milk Investors…

A2 Milk’s demand commentary was unequivocally strong. Year‑to‑date offtake trends in 3Q26 were similar to or better than 1H26, with momentum across all product categories and regions. China label IMF continued to benefit from improved new‑user recruitment, aided by the My Little Pony marketing campaign, while later‑stage products saw growth from prior share gains and the success of the company’s new kids’ nutrition range.

English‑label IMF also performed well, with a2 Platinum and a2 Genesis delivering strong growth across all stages, particularly through cross‑border e‑commerce (CBEC) channels. The company noted that a2 Genesis (around 6% of CBEC sales) is experiencing temporary availability issues due to high demand, but production at Pōkeno is resuming following capital works. The problem is not that the demand engine is not firing, because it is. The problem is getting product to shelves.

The Supply Chain Bottleneck: A Convergence of Unhelpful Variables

The company outlined several factors behind the current in‑market product availability issues. Demand has been stronger than expected, partly because competitor product recalls have pushed consumers toward A2 Milk.

Freight availability has been affected by the Middle East conflict, which has tightened air freight capacity and increased costs, while sea freight allocations remain inconsistent. Production challenges at Synlait earlier in the year left A2 Milk with low inventory levels, and although production has now returned to target levels, a significant backlog of unfilled purchase orders remains. This backlog has been compounded by Synlait’s reduced capacity following the sale of its North Island assets.

Quality‑assurance processes have also lengthened. Enhanced cereulide testing requirements for ingredient suppliers and IMF manufacturers are extending release times, and customs clearance in China has slowed because of higher inspection and sampling rates across the industry.

Individually, each factor is manageable. But in combination, they create a timing mismatch that A2 Milk cannot unwind quickly given the long lead times inherent in IMF production and distribution. The company is working with supply chain partners in New Zealand and China to accelerate product flows, but it now expects material in‑market shortages of China label IMF during April and May.

A2 Milk’s FY26 Outlook: A Reset Rather Than a Rewrite

The revised guidance reflects the operational reality. Revenue growth is now expected to be in the low‑ to mid‑double‑digit range rather than the previously indicated mid‑double‑digit outcome. EBITDA margin guidance has been reduced to 14.0–14.5%, and NPAT is now expected to be similar to or down on FY25 rather than up. Cash conversion has been cut to 50%, largely because of delayed receipts and extended release times. Capital expenditure remains unchanged at $60–80m.

The downgrade is meaningful, but the company emphasised that the supply chain issues are primarily timing‑related and one‑off in nature. The broader transformation program at Pōkeno remains on track, with capital upgrades, capability building and China label registration amendments progressing ahead of a planned production ramp‑up in the first half of FY27.

For long‑term investors, the key question is whether today’s update reflects structural fragility or simply the growing pains of a business transitioning to a more vertically integrated supply chain. The evidence still points to the latter.

Market Reaction: Why a 15% Sell‑Off?

The share price reaction reflects three sensitivities that have become embedded in the A2 Milk investment narrative. First, the company’s exposure to the China IMF channel means that any disruption, even temporary, triggers a disproportionate market response. Second, after several years of volatility, investors have a low tolerance for operational surprises. Third, the downgrade to cash conversion raises questions about working‑capital management and the timing of Synlait‑related receipts.

The market is effectively pricing in a higher execution risk premium. Whether that repricing persists will depend on how quickly A2 Milk can normalise product availability and demonstrate that the backlog at Synlait (A2’s manufacturing partner) is genuinely clearing.

What about for Synlait?

Synlait issued its own update in response to A2 Milk’s announcement. The company acknowledged the operational pressures referenced by its largest customer and reiterated that enhanced testing implemented earlier in the year has extended product release times and increased working‑capital requirements.

Synlait has been working through supply chain impacts with A2 Milk’s support, and production has recently returned to targeted levels. The company is now rebuilding customer inventory following previously reported manufacturing challenges.

Synlait did not provide FY26 guidance, consistent with its September 2025 full‑year results, citing the dynamic nature of the global IMF industry. Today’s update reinforces that the same risks affecting A2 Milk—product release delays, clearance times, supply chain complexity, regulatory shifts and geopolitical uncertainty—also affect Synlait.

For Synlait shareholders, the central issue is operational resilience. The company’s ability to consistently meet A2 Milk’s requirements is fundamental to its recovery narrative. While production has returned to target levels, the backlog of unfilled orders and the reduced capacity following asset sales highlight the fragility of the current operating base.

A2 Milk’s update is therefore a double‑edged sword for Synlait. It confirms improving production performance, but it also underscores the consequences of earlier manufacturing challenges and the importance of restoring reliability.

Our Investment View: A Short‑Term Shock Rather Than a Long‑Term Break

Today’s announcements from A2 Milk and Synlait highlight the complexity of the IMF supply chain and the sensitivity of both companies to operational timing. The demand backdrop remains robust, and neither company is signalling a structural deterioration in category dynamics or brand equity.

The near‑term earnings impact is real, and the market reaction reflects understandable frustration. But the underlying investment case for A2 Milk—premium brand strength, improving channel execution and a maturing supply chain—remains intact. For Synlait, the path is narrower, but today’s confirmation of production returning to target levels is a necessary step in rebuilding credibility.

The next two months will be critical. If A2 Milk can restore product availability by early FY27 and Synlait can demonstrate sustained operational stability, today’s sell‑off may ultimately prove to be an overreaction rather than a reset of long‑term value.